BRAINSTORM CELL THERAPEUTICS INC. short interest in 2021
In 2021, BRAINSTORM CELL THERAPEUTICS INC.'s disclosed short interest ran from 15.22% of shares outstanding on 15 Jan 2021 to 3.78% on 31 Dec 2021, a change of -11.44 percentage points. The year's high was 15.22% on 15 Jan 2021 and its low 2.02% on 15 Nov 2021, averaging 7.45% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.22 days on 28 May 2021. Full history: BRAINSTORM CELL THERAPEUTICS INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
2021 in figures
- Start of year
- 15.22% (15 Jan 2021)
- End of year
- 3.78% (31 Dec 2021)
- Change
- -11.44 pp
- High
- 15.22% (15 Jan 2021)
- Low
- 2.02% (15 Nov 2021)
- Average
- 7.45%
- Highest days to cover
- 19.22 (28 May 2021)
- SEC filings marked
- 7
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 15.22% | 10.62 | |
| 29 Jan 2021 | 14.78% | 2.89 | |
| 12 Feb 2021 | 11.82% | 3.34 | 10-K filed, results (8-K) |
| 26 Feb 2021 | 11.00% | 2.80 | |
| 15 Mar 2021 | 11.81% | 5.60 | |
| 31 Mar 2021 | 12.30% | 3.07 | |
| 15 Apr 2021 | 10.27% | 11.20 | |
| 30 Apr 2021 | 10.52% | 7.08 | 10-Q filed, results (8-K) |
| 14 May 2021 | 12.06% | 12.58 | |
| 28 May 2021 | 9.82% | 19.22 | |
| 15 Jun 2021 | 9.87% | 8.68 | |
| 13 Aug 2021 | 2.87% | 4.39 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 2.87% | 9.21 | |
| 15 Sep 2021 | 2.53% | 5.56 | |
| 30 Sep 2021 | 2.70% | 10.18 | |
| 15 Oct 2021 | 2.31% | 9.40 | |
| 29 Oct 2021 | 2.05% | 5.11 | |
| 15 Nov 2021 | 2.02% | 5.99 | 10-Q filed |
| 30 Nov 2021 | 2.57% | 1.62 | |
| 15 Dec 2021 | 3.38% | 1.13 | |
| 31 Dec 2021 | 3.78% | 3.11 |
See also: BRAINSTORM CELL THERAPEUTICS INC.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.